Genus PLC
12 November 2007
12 November 2007
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, JAPAN, CANADA, AUSTRALIA OR THE
REPUBLIC OF IRELAND
Genus plc
('Genus' or 'the Company')
Commencement of trading on the Official List
Genus plc, a world leading animal genetics company, is pleased to announce that
admission to the Official List of the UK Listing Authority and the London Stock
Exchange's main market for listed securities of 59,204,190 ordinary shares of 10
pence ('Ordinary Shares') has occurred ('Admission') and that trading in its
Ordinary Shares became effective from 8.00 am today. The Company's FTSE
classification is Biotechnology.
Copies of the prospectus dated 6 November 2007, published in connection with
Admission are available from the 'Investors' section of the Company's website at
www.genusplc.com. The prospectus has also been submitted to the UKLA's Document
Viewing Facility situated at: Financial Services Authority, 25 The North
Colonnade, Canary Wharf, London, E14 5HS.
Enquiries:
Genus plc Tel: 01256 345970
Richard Wood, Chief Executive
Martin Boden, Finance Director
Landsbanki Securities (UK) Limited Tel: 020 7426 9000
Sponsor & Joint Broker
Shaun Dobson
Buchanan Communications Tel: 020 7466 5000
Charles Ryland / Suzanne Brocks
About Genus
Genus creates and sells added value products for livestock farming and food
producers by creating advances to animal breeding through biotechnology. Its
non-Genetically Modified Organism (GMO) technology is applicable across all
livestock species but is only commercialised by Genus in the bovine and porcine
farming sectors.
Genus' worldwide sales are made in seventy countries under the trade marks 'ABS'
(dairy and beef cattle) and 'PIC' (pigs) and comprise semen and breeding animals
with superior genetics to those animals currently in production. Customers
produce offspring with greater production efficiency, milk and meat output and
quality and use these to supply the global dairy and meat supply chain.
Genus' competitive edge has been created from the ownership and control of
proprietary lines of breeding animals, the biotechnology used to improve them
and the Group's global production and distribution network.
Headquartered in Basingstoke, England, Genus companies operate in 30 countries
on five continents, with research laboratories located in Madison, USA.
This information is provided by RNS
The company news service from the London Stock Exchange